These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 28618015

  • 1. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL, Wong GL, Kazankov K, Sandahl T, Møller HJ, Hamilton-Dutoit S, George J, Chan HL, Grønbaek H.
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [Abstract] [Full Text] [Related]

  • 2. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
    Andersen ES, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N.
    Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
    [Abstract] [Full Text] [Related]

  • 3. Macrophage markers soluble CD163 and soluble mannose receptor are associated with liver injury in patients with paracetamol overdose.
    Siggaard CB, Kazankov K, Rødgaard-Hansen S, Møller HJ, Donnelly MC, Simpson KJ, Grønbaek H.
    Scand J Gastroenterol; 2019 May; 54(5):623-632. PubMed ID: 31067143
    [Abstract] [Full Text] [Related]

  • 4. Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients.
    Kjærgaard AG, Rødgaard-Hansen S, Dige A, Krog J, Møller HJ, Tønnesen E.
    PLoS One; 2014 May; 9(3):e92331. PubMed ID: 24637679
    [Abstract] [Full Text] [Related]

  • 5. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O.
    J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
    [Abstract] [Full Text] [Related]

  • 6. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K, Barrera F, Møller HJ, Bibby BM, Vilstrup H, George J, Grønbaek H.
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [Abstract] [Full Text] [Related]

  • 7. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
    Kimer N, Gudmann NS, Pedersen JS, Møller S, Nielsen MJ, Leeming DJ, Karsdal MA, Møller HJ, Bendtsen F, Grønbæk H.
    PLoS One; 2018 Aug; 13(9):e0203200. PubMed ID: 30183743
    [Abstract] [Full Text] [Related]

  • 8. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
    Lund Laursen T, Brøckner Siggard C, Kazankov K, Damgaard Sandahl T, Møller HJ, Ong A, Douglas MW, George J, Tarp B, Hagelskjaer Kristensen L, Lund Laursen A, Hiramatsu A, Nakahara T, Chayama K, Grønbaek H.
    Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
    [Abstract] [Full Text] [Related]

  • 9. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma.
    Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ.
    Leuk Res; 2015 Sep; 39(9):971-5. PubMed ID: 26169445
    [Abstract] [Full Text] [Related]

  • 10. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.
    Rainer F, Horvath A, Sandahl TD, Leber B, Schmerboeck B, Blesl A, Groselj-Strele A, Stauber RE, Fickert P, Stiegler P, Møller HJ, Grønbaek H, Stadlbauer V.
    Aliment Pharmacol Ther; 2018 Mar; 47(5):657-664. PubMed ID: 29266346
    [Abstract] [Full Text] [Related]

  • 11. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K, Tordjman J, Møller HJ, Vilstrup H, Poitou C, Bedossa P, Bouillot JL, Clement K, Grønbaek H.
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [Abstract] [Full Text] [Related]

  • 12. Increased CD163 expression is associated with acute-on-chronic hepatitis B liver failure.
    Ye H, Wang LY, Zhao J, Wang K.
    World J Gastroenterol; 2013 May 14; 19(18):2818-25. PubMed ID: 23687420
    [Abstract] [Full Text] [Related]

  • 13. Divergent effects on macrophage biomarkers soluble CD163 and CD206 in axial spondyloarthritis.
    Heftdal LD, Loft AG, Hendricks O, Ashouri Christiansen A, Schiøttz-Christensen B, Arnbak B, Jurik AG, Østgård R, Winding Deleuran B, Møller HJ, Greisen SR.
    Scand J Clin Lab Invest; 2018 Oct 14; 78(6):483-489. PubMed ID: 30176763
    [Abstract] [Full Text] [Related]

  • 14. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    Grønbæk H, Rødgaard-Hansen S, Aagaard NK, Arroyo V, Moestrup SK, Garcia E, Solà E, Domenicali M, Piano S, Vilstrup H, Møller HJ, CANONIC study investigators of the EASL-CLIF Consortium.
    J Hepatol; 2016 Apr 14; 64(4):813-22. PubMed ID: 26639396
    [Abstract] [Full Text] [Related]

  • 15. The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients.
    Dultz G, Gerber L, Zeuzem S, Sarrazin C, Waidmann O.
    J Viral Hepat; 2016 Apr 14; 23(4):267-73. PubMed ID: 26554542
    [Abstract] [Full Text] [Related]

  • 16. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N.
    J Infect Dis; 2018 Sep 22; 218(9):1394-1403. PubMed ID: 29868909
    [Abstract] [Full Text] [Related]

  • 17. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.
    Bossen L, Rebora P, Bernuzzi F, Jepsen P, Gerussi A, Andreone P, Galli A, Terziroli B, Alvaro D, Labbadia G, Aloise C, Baiocchi L, Giannini E, Abenavoli L, Toniutto P, Marra F, Marzioni M, Niro G, Floreani A, Møller HJ, Valsecchi MG, Carbone M, Grønbaek H, Invernizzi P.
    Liver Int; 2020 Jun 22; 40(6):1408-1414. PubMed ID: 32279422
    [Abstract] [Full Text] [Related]

  • 18. The macrophage activation marker sMR as a diagnostic and prognostic marker in patients with acute infectious disease with or without sepsis.
    Marie Relster M, Gaini S, Møller HJ, Johansen IS, Pedersen C.
    Scand J Clin Lab Invest; 2018 May 22; 78(3):180-186. PubMed ID: 29383956
    [Abstract] [Full Text] [Related]

  • 19. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
    Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Younes R, Esmaili S, Eslam M, McLeod D, Bibby BM, Vilstrup H, George J, Grønbaek H.
    Liver Int; 2016 Oct 22; 36(10):1549-57. PubMed ID: 27102725
    [Abstract] [Full Text] [Related]

  • 20. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
    Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S.
    J Dermatol Sci; 2012 Oct 22; 68(1):45-51. PubMed ID: 22884782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.